Background: Since December 2019, an outbreak of a novel coronavirus infection has
been reported, drawing immediate attention from the World Health Organization. SARS-CoV-2, as
the cause of COVID-19 with extra potency of transmission, has led to global concern. Currently,
more than a thousand clinical trials have focused on achieving a protective or preventive approach
against the virus, among which cell-based therapies seem to be significantly applicable.
Objective: We aimed to summarize cell-based therapy against COVID-19 and compare the applicable
methods and possible outcomes.
Methods: The current clinical trials based on cell-based therapies are summarized according to the
cell sorting applications. The possible approaches, advantages, and opinions are discussed.
Results and Conclusion: Cell-based therapy has already brought some hope. It needs to meet the
following features: 1) The long-term protection data after treatment must be provided by stem cell
investigators. 2) A design of multivalent antigens based on immunoinformatic prediction is suggested
to engineer T-cell and dendritic cell-based therapies in order to deliver the most immunogenic
conserved epitopes. 3) According to the sophisticated procedure, the preparation of the cells must
be supported by authorities in order to decrease the cost and the time of the whole process.